Logo

The US FDA Approves Jaguar Health’s Clinical Trial Protocol for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs

Share this
Jaguar Health

The US FDA Approves Jaguar Health’s Clinical Trial Protocol for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs

Shots:

  • The US FDA has agreed to the clinical trial design and conduct proposed by Jaguar Health for the evaluation of Canalevia-CA1 (crofelemer delayed-release tablets) for the treatment of CT-induced diarrhea (CID) in dogs. The company expects to receive the US FDA’s full approval based on this trial
  • Earlier in Dec 2021, Jaguar received the US FDA’s conditional approval for Canalevia-CA1 to treat CID in dogs. Later in Dec 2023, the conditional approval was renewed to a validity up until 21st Dec 2024
  • Canalevia-CA1 is an oral plant-based (canine-specific formulation of crofelemer) prescription product conditionally approved by the US FDA, received through the MUMS pathway

Ref: Jaguar Health | Image: Jaguar Health

Related News:- Jaguar Health’s Canalevia-CA1 Receives Conditional Approval Renewal from the US FDA for Chemotherapy-Induced Diarrhea in Dogs

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions